Raya Mawad

Oncology
1221 Madison St Fl 10
Seattle, WA 98104

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications

Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms.

Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms.

Journal: Leukemia
Published: January 16, 2026

National Landscape of Logistical and Nonmedical Requirements for Transplantation and Cellular Therapy.

National Landscape of Logistical and Nonmedical Requirements for Transplantation and Cellular Therapy.

Journal: Transplantation and cellular therapy
Published: July 31, 2025

CLO25-058: First-in-Human, Multicenter Phase 1 Study of the Bromodomain 2 Inhibitor ABBV-744 in Relapsed/Refractory Acute Myeloid Leukemia.

CLO25-058: First-in-Human, Multicenter Phase 1 Study of the Bromodomain 2 Inhibitor ABBV-744 in Relapsed/Refractory Acute Myeloid Leukemia.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 28, 2025

Prognostic significance of chromosomal genomic array testing in adults with newly-diagnosed acute lymphoblastic leukemia.

Prognostic significance of chromosomal genomic array testing in adults with newly-diagnosed acute lymphoblastic leukemia.

Journal: Leukemia & lymphoma
Published: September 19, 2024

Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia.

Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia.

Journal: Blood advances
Published: June 12, 2023

The role of adjuvant chemotherapy in the management of acute promyelocytic leukemia differentiation syndrome.

The role of adjuvant chemotherapy in the management of acute promyelocytic leukemia differentiation syndrome.

Journal: Frontiers in oncology
Published: April 03, 2022

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.

Journal: Blood
Published: October 06, 2020

Pembrolizumab immunotherapy for relapsed CNS Lymphoma.

Pembrolizumab immunotherapy for relapsed CNS Lymphoma.

Journal: Leukemia & lymphoma
Published: March 25, 2020

Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.

Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.

Journal: British journal of haematology
Published: June 23, 2015

Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome.

Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome.

Journal: American journal of hematology
Published: February 11, 2015

Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment.

Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment.

Journal: Blood
Published: December 30, 2014

A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age.

A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age.

Journal: British journal of haematology
Published: December 30, 2014
Showing 1-12 of 19

Last Updated: 09/26/2026